Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics is a commercial-stage medical diagnostics technology company that is poised for significant growth as it focuses on the millions of patients at risk of developing esophageal cancer. With an estimated addressable market opportunity of $2 billion in the US alone and strong clinical support for its products, the company is well-positioned for success. Recent positive news and progress with Medicare and commercial payors, as well as plans to expand its sales force and increase volume growth, indicate potential for significant revenue growth in the near future. However, risks such as reimbursement and commercial execution should be monitored. Overall, Lucid Diagnostics presents a compelling investment opportunity with strong growth potential.

Bears say

Lucid Diagnostics is currently facing a multitude of risks that could hinder the attainment of its share price target, including the potential for balance sheet and liquidity risks, slow commercialization of its products, and failure to gain necessary regulatory approvals and reimbursement for its products. Additionally, the company's current valuation may not accurately reflect its high risks and potential for volatility. Its current flagship product, EsoGuard, may have significant potential in the market for esophageal cancer screening, but its success is not guaranteed and will heavily rely on Medicare coverage and adoption by healthcare providers. Overall, while there may be some catalysts for the stock in the near future, the risks involved make it difficult to have a positive outlook on the company's stock.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Aug 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.